High Quality Olaparib CAS 763113-22-0 Powder Fast Shipping

Olaparib More Info

1. What is Olaparib?

Olaparib is an oral anticancer medication used to treat certain types of cancers that are associated with defective DNA repair mechanisms, particularly in patients with BRCA1 or BRCA2 mutations. It belongs to a class of targeted therapies known as PARP inhibitors. Olaparib helps prevent cancer cells from repairing their DNA, leading to cell death — especially in cancer cells already impaired in DNA repair.

2. Brand Name:

Lynparza®

3. Pharmacologic Class:

Poly (ADP-ribose) polymerase (PARP) inhibitor

Antineoplastic (anticancer) agent

4. Mechanism of Action:

Olaparib inhibits PARP enzymes (mainly PARP-1 and PARP-2), which are involved in repairing single-strand breaks in DNA. In tumors with BRCA1 or BRCA2 mutations, the homologous recombination repair (HRR) pathway is defective. Olaparib blocks the backup DNA repair pathway (mediated by PARP), leading to accumulation of DNA damage, genomic instability, and ultimately cancer cell death. This mechanism is called synthetic lethality.

5. Approved Indications (Uses):

As of the latest FDA and EMA approvals, Olaparib is indicated for treatment of the following cancers:

A. Ovarian Cancer:

Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy

Maintenance treatment in newly diagnosed, advanced BRCA-mutant ovarian cancer

Treatment of BRCA-mutated advanced ovarian cancer after 3 or more lines of chemotherapy

B. Breast Cancer:

Germline BRCA-mutated, HER2-negative metastatic breast cancer; previously treated with chemotherapy (and endocrine therapy if hormone receptor-positive)

C. Pancreatic Cancer:

Germline BRCA-mutated metastatic pancreatic adenocarcinoma; maintenance treatment after at least 16 weeks of initial platinum-based chemotherapy without disease progression

D. Prostate Cancer:

Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations (e.g., BRCA1, BRCA2, ATM), after prior treatment with enzalutamide or abiraterone

6. Dosage and Administration:

General adult dosing (may vary by indication):

300 mg orally twice daily (total daily dose: 600 mg)

Continue until disease progression or unacceptable toxicity

Administration tips:

Take with or without food

Swallow tablets whole; do not chew, crush, or split

Avoid taking with grapefruit or Seville oranges (may increase drug levels)

Different formulations:

Tablets and capsules are NOT interchangeable (due to differences in formulation and bioavailability)

7. Available Dosage Forms and Strengths:

Tablets (most current formulation):

100 mg

150 mg

Older capsule form (not interchangeable with tablets):

50 mg (less preferred due to higher pill burden)

8. Common Side Effects:

Hematologic:

Anemia (very common)

Neutropenia

Thrombocytopenia

Gastrointestinal:

Nausea and vomiting

Diarrhea or constipation

Decreased appetite

Other common effects:

Fatigue or asthenia (most frequently reported)

Headache

Dysgeusia (altered taste)

9. Serious Side Effects and Risks:

Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Rare but potentially fatal

Pneumonitis (inflammation of lung tissue): Rare; may present with cough and shortness of breath

Severe anemia or bone marrow suppression

Patients should be monitored regularly with:

Complete blood counts (CBC): Baseline and monthly or more frequently as indicated

Signs and symptoms of pulmonary toxicity or secondary malignancies

10. Warnings and Precautions:

Risk of MDS/AML

Embryo-fetal toxicity: Avoid in pregnancy; use effective contraception during treatment and for 6 months after (females)

Male patients with partners of childbearing potential should use contraception during and for 3 months after the last dose

11. Contraindications:

Known hypersensitivity to Olaparib or any of its components

Pregnancy and breastfeeding are discouraged

12. Drug Interactions:

Metabolized primarily by CYP3A4 enzymes
Avoid using with:
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) → ↑ Olaparib levels
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) → ↓ Olaparib effectiveness

If co-administration is necessary:

Adjust dose based on interaction risk and patient tolerance

13. Use in Pregnancy and Lactation:

Pregnancy:

Category D (U.S.): Positive evidence of fetal risk

Avoid use during pregnancy; conduct pregnancy test before starting

Breastfeeding:

Unknown if excreted in human milk; discontinue breastfeeding during therapy and for 1 month after the last dose

14. Use in Special Populations:

Renal impairment: No dose adjustment for mild/moderate impairment; reduce dose in severe renal impairment

Hepatic impairment: Use cautiously in moderate impairment; not recommended in severe hepatic impairment

15. Monitoring Parameters:

CBC and differential (baseline, monthly, or more frequently)

Renal and hepatic function (depending on patient history)

Signs of MDS/AML or lung toxicity

16. Storage:

Store at room temperature (20–25°C / 68–77°F)

Keep in original container, away from light and moisture

17. Summary of Key Advantages:

✅ First-in-class oral PARP inhibitor
✅ Approved for multiple BRCA-mutated cancers
✅ Proven efficacy in maintenance therapy post-chemotherapy
✅ Non-cytotoxic, targeted mechanism
✅ Can delay disease progression in responsive tumors

18. Limitations:

May cause significant fatigue and anemia

Requires genetic testing (e.g., BRCA or other HRR mutations) for use in many cases

Possibility of severe long-term adverse effects, like MDS/AML

Tablet and capsule forms are not interchangeable

Summary:

Olaparib (Lynparza) is a targeted oral therapy that works as a PARP inhibitor to interfere with DNA repair in cancer cells, leading to cancer cell death. It is approved for several BRCA-mutated cancer types, including ovarian, breast, pancreatic, and prostate cancer. Its selective mechanism allows it to be effective in maintenance therapy as well as in active treatment. However, it carries risks like bone marrow suppression and requires regular monitoring.

ents.

Product Image

FAQ

Q1. Can I get a free sample?

We can send you a samll free sample, and you only need to pay for the shipping cost.

Q2. What is the HyperChem payment term?

T/T in advance
LC at sight
DP at sight

Bank transfer

PayPal

Bitcoin...

Q3. What is HyperChem shipment policy?

Our policy is to strive for the quickest shipment time possible.

For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.

Q4. What is HyperChem shipment term?

By Express  
FedEx  UPS  DHL  EMS                               
Fast: 3-7 days around, high cost, door to door service

By Air                                        
Suitable for more than 50kg 
Fast: 3-7 days, hight cost, port to port, professional broker needed 

By Sea
Suitable for more than 500kg      
Fast: 7-45 days, low cost, port to port, professional broker needed 

We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.

Q5. What HyperChem will provide after shipment?

For sample orders: 
After shipment is done, an timely email including:

1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice

For commercial orders:
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.